Patents by Inventor Barbara Enenkel
Barbara Enenkel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130177943Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: ApplicationFiled: February 22, 2013Publication date: July 11, 2013Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventor: Barbara ENENKEL
-
Patent number: 8466271Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: GrantFiled: July 22, 2009Date of Patent: June 18, 2013Assignee: Boehringer Ingelheim Pharma GmbH & Co, KGInventor: Barbara Enenkel
-
Patent number: 8404486Abstract: The present invention relates to nucleotide sequences, which are variants of att recombination sequences, involved in sequence-specific recombination of DNA in eukaryotic cells, whereby sequence specific recombination is performed by a bacteriophage lambda integrase Int. Such att recombination sequences being e.g. attP.b, attP.a, attL.a, attR.a and attR.b. The present invention further relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int, whereby at least one of said first or second DNAs is an att recombination sequence being e.g. attP.b, attP.a, attL.a, attR.a or attR.b.Type: GrantFiled: November 28, 2008Date of Patent: March 26, 2013Assignee: Boehringer Ingelheim International GmbHInventor: Barbara Enenkel
-
Publication number: 20130011391Abstract: Provided herein, in one aspect, are antibodies that immunospecifically bind to PSGL-1, polynucleotides comprising nucleotide sequences encoding such antibodies, and expression vectors and host cells for producing such antibodies. Also provided herein are kits and pharmaceutical compositions comprising antibodies that specifically bind to PSGL-1, as well as methods of treating a disorder or disease caused by or associated with increased proliferation and/or numbers of activated T cells using the antibodies described herein.Type: ApplicationFiled: June 12, 2012Publication date: January 10, 2013Applicant: AbGenomics Cooperatief U.A.Inventors: Stefan Bassarab, Barbara Enenkel, Patrick Garidel, Heidrun Schott, Sanjaya Singh, Tobias Litzenburger
-
Patent number: 8338179Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.Type: GrantFiled: January 4, 2008Date of Patent: December 25, 2012Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
-
Publication number: 20120190065Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through introduction of nucleic acids encoding UBF or reducing expression of NoRC proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: May 12, 2010Publication date: July 26, 2012Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore Florin, Barbara Enenkel, Martin Fussenegger, Hitto Kaufmann, Raffaella Santoro
-
Publication number: 20110312029Abstract: The invention concerns novel regulatory elements as well as related vectors and cells. Furthermore, it relates to methods of improving expression of polypeptides from nucleic acids such as cloned genes and to the production of various polypeptides in host cells using said novel regulatory elements. Additionally, the invention relates to uses of said novel regulatory elements as insulators, in gene therapy or for improving host cell lines.Type: ApplicationFiled: July 22, 2009Publication date: December 22, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO, KGInventor: Barbara Enenkel
-
Publication number: 20110281301Abstract: The invention concerns the field of protein production and cell culture technology. It describes a method of producing a heterologous protein of interest in a cell comprising a. Increasing the expression or activity of a secretion enhancing gene, and b. Increasing the expression or activity of an anti-apoptotic gene, and c. Effecting the expression of said protein of interest, whereby the secretion enhancing gene is a gene encoding a protein whose expression or activity is induced during one of the following cellular processes: plasma-cell differentiation, unfolded protein response (UPR), endoplasmic reticulum overload response (EOR).Type: ApplicationFiled: October 6, 2008Publication date: November 17, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Hitto Kaufmann, Eric Becker, Lore Florin, Barbara Enenkel, Kerstin Sautter, Rebecca Bischoff
-
Publication number: 20110250640Abstract: A new method for selecting clones and recloning mammalian cells which are of importance for the production of biopharmaceuticals, preferably hamster or mouse myeloma cells, with a high degree of automation and throughput. The invention relates to methods of depositing and replicating single cell clones of the cells in question. The invention also relates to methods of preparing proteins using cells which have been obtained and replicated by single cell deposition as well as compositions which allow the replication of single cells.Type: ApplicationFiled: October 7, 2010Publication date: October 13, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventors: Ralf OTTO, Barbara ENENKEL, Juergen FIEDER, Thomas KRIEG
-
Publication number: 20110201785Abstract: The invention relates to a method for optimizing the biophysical properties of molecules and derivatives of the Ig superfamily. The method is characterized in that as yet unrecognized helical structural elements with unknown structural, stability and folding roles have been identified as important determinants of correct and efficient structuring of antibody domains. The novel process for positively influencing the antibody properties and properties of other proteins that have the Ig folding pattern now consists of optimizing the properties of the short helical elements and in the transplantation of these elements between Ig domains.Type: ApplicationFiled: June 30, 2009Publication date: August 18, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Johannes Buchner, Matthias Feige, Dorothee Ambrosius, Barbara Enenkel
-
Publication number: 20110189729Abstract: The present invention relates to novel nucleotide sequences, which are variants of att recombination sequences, involved in sequence-specific recombination of DNA in eukaryotic cells, whereby sequence specific recombination is performed by a bacteriophage lambda integrase Int. Such novel att recombination sequences being e.g. attP.b, attP.a, attL.a, attR.a and attR.b. The present invention further relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int, whereby at least one of said first or second DNAs is a novel att recombination sequences being e.g. attP.b, attP.a, attL.a, attR.a and attR.b.Type: ApplicationFiled: November 28, 2008Publication date: August 4, 2011Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KGInventor: Barbara Enenkel
-
Patent number: 7968341Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.Type: GrantFiled: November 28, 2003Date of Patent: June 28, 2011Assignees: Boehringer Ingelheim Pharma GmbH & Co KGInventors: Peter Dröge, Barbara Enenkel
-
Publication number: 20110124108Abstract: The invention concerns the field of cell culture technology. It concerns production host cell lines with increased expression of ribosomal RNA (rRNA) achieved through reducing expression of NoCR proteins, especially of TIP-5. Those cell lines have improved secretion and growth characteristics in comparison to control cell lines. The invention further concerns a method of producing proteins using the cells generated by the described method.Type: ApplicationFiled: May 13, 2010Publication date: May 26, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Lore FLORIN, Barbara ENENKEL, Martin FUSSENEGGER, Hitto KAUFMANN, Raffaella SANTORO
-
Publication number: 20100311121Abstract: The invention relates to DNA-sequences, especially transcription- or expression-enhancing elements (TE elements) and their use on an expression vector in conjunction with an enhancer, a promoter, a product gene and a selectable marker. The invention describes Sequence No. 1 and TE elements TE-01, -02, -03, -04, -06, -07, -08, -10, -11 or -12. Because of their small size, TE-06, TE-07 or TE-08 are particularly preferred. Sequence No. 1 originates from a sequence region located upstream from the coding region of the Ub/S27a gene from CHO cells. TE elements bring about an increase in the expression of the product gene, particularly when stably integrated in the eukaryotic genome, preferably the CHO-DG44 genome. Chromosomal positional effects are thereby overcome, shielded or cancelled out. In this way the proportion of high producers in a transfection mixture and also the absolute expression level are increased up to seven-fold.Type: ApplicationFiled: July 23, 2010Publication date: December 9, 2010Applicant: Boehringer Ingelheim Pharma GmbH & Co.KGInventors: Barbara ENENKEL, Kerstin SAUTTER
-
Patent number: 7846732Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.Type: GrantFiled: November 17, 2005Date of Patent: December 7, 2010Assignees: Boehringer Ingelheim Pharma KGInventors: Peter Dröge, Barbara Enenkel
-
Publication number: 20100297697Abstract: The invention relates to methods of increasing the titre of a protein of interest in a cell as well as the improved production and purification of optimised biomolecules, one component of which is the domain CH3. A frequently observed effect in biomolecules is the cleaving of the C-terminal amino acid(s), e.g. the C-terminal lysine. The usually incomplete processing of the heavy chain of antibodies for example leads to product heterogeneity. To prevent this product heterogeneity the corresponding codon of the C-terminal lysine of the heavy antibody chain has been deleted by recombinant DNA technology. These optimised antibodies lead to a product titre which is higher than in the wild-type. In addition, they prove advantageous during purification by having better elution characteristics as a result of the reduced charge heterogeneity.Type: ApplicationFiled: August 28, 2008Publication date: November 25, 2010Applicant: BOEHRINGER INGELHEIM PHARMA GMBH & CO KGInventors: Dorothee Ambrosius, Barbara Enenkel, Christian Eckermann
-
Patent number: 7833787Abstract: A new method for selecting clones and recloning mammalian cells which are of importance for the production of biopharmaceuticals, preferably hamster or mouse myeloma cells, with a high degree of automation and throughput. The invention relates to methods of depositing and replicating single cell clones of the cells in question. The invention also relates to methods of preparing proteins using cells which have been obtained and replicated by single cell deposition as well as compositions which allow the replication of single cells.Type: GrantFiled: August 19, 2004Date of Patent: November 16, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Ralf Otto, Barbara Enenkel, Juergen Fieder, Thomas Krieg
-
Patent number: 7732181Abstract: The invention relates to modified neomycin phosphotransferase genes and their use in a selection method for high-producing recombinant cells. The invention further relates to expression vectors which contain a modified neomycin phosphotransferase gene and a gene of interest functionally linked to a heterologous promoter and a method of preparing heterologous gene products using these expression vectors.Type: GrantFiled: January 4, 2008Date of Patent: June 8, 2010Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Barbara Enenkel, Juergen Fieder, Ralf Otto, Kerstin Sautter, Klaus Bergemann
-
Publication number: 20090162900Abstract: An expression vector for eukaryotic cells comprising a gene which codes for a protein of interest, functionally linked to a hamster-ubiquitin/S27a-promoter and a gene which codes for a fluorescent protein. Preferably the expression vector also contains an amplifiable selectable marker gene. The invention also describes host cells, preferably mammalian cells, which have been transfected with the expression vector, processes for producing heterologous gene products and a method of selecting high-producing cells.Type: ApplicationFiled: February 15, 2008Publication date: June 25, 2009Inventors: Barbara ENENKEL, Juergen Fieder, Ralf Otto, Stefanos Grammatikos
-
Patent number: 7491539Abstract: The present invention relates to a method of sequence-specific recombination of DNA in eukaryotic cells, comprising the introduction of a first DNA comprising a nucleotide sequence containing at least one recombination sequence into a cell, introducing a second DNA comprising a nucleotide sequence containing at least one further recombination sequence into a cell, and performing the sequence specific recombination by a bacteriophage lambda integrase Int.Type: GrantFiled: December 5, 2002Date of Patent: February 17, 2009Assignee: Boehringer Ingelheim Pharma KGInventors: Peter Dröge, Barbara Enenkel